Literature DB >> 870271

Digoxin kinetics during furosemide administration.

A D Malcolm, F Y Leung, J C Fuchs, J E Duarte.   

Abstract

The urinary excretion of a 0.75-mg oral dose of digoxin was assessed in 8 healthy men during a control 5-day period and then, after a washout period of at least 2 wk, during a 5-day period when the subjects also took oral furosemide, 40 mg daily. Analysis of the raw data by a paired Student's test and analysis of variance of log-transformed urinary digoxin excretion data revealed no significant difference attributable to the addition of furosemide (F = 1.16; df = 1,21). The treatment by day interaction showed the slopes to be consistent between the two treatments. It seems that in the presence of normal renal function there is no need to alter loading or maintenance doses of digoxin when furosemide is also given. Analysis of variance with log transformation of data is suggested as a practical approach to handling digoxin urinary excretion results when the transformation linearizes the data through examination by the method of orthogonal polynomials.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 870271     DOI: 10.1002/cpt1977215567

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

Review 1.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

2.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

3.  Digoxin, whole body potassium and the electrocardiogram.

Authors:  P H Joubert; F O Müller; F W van Rijssen; J Malan; M P Iturralde; O R van Reenen
Journal:  Eur J Clin Pharmacol       Date:  1978-11-16       Impact factor: 2.953

4.  Renal clearance of digoxin in man after sodium loading or furosemide treatment.

Authors:  M A Naafs; C van der Hoek; W Schopman; S van Duin; G Koorevaar; J Silberbusch
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.